Grufity logo
Grufity logo
HCWB

HCWB - HCW Biologics Inc. Stock Price, Fair Value and News

$3.23+0.08 (+2.54%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

5/100

HCWB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

HCWB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HCWB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HCWB Price Action

Last 7 days

29.2%

Last 30 days

-29.5%

Last 90 days

617.8%

Trailing 12 Months

-23.8%

HCWB RSI Chart

HCWB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HCWB Valuation

Market Cap

21.8M

Price/Earnings (Trailing)

-9.5

Price/Sales (Trailing)

6.56

EV/EBITDA

-0.72

Price/Free Cashflow

-1.9

HCWB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HCWB Fundamentals

HCWB Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

302.78%

Rev. Growth (Qtr)

23.14%

HCWB Earnings

Earnings (TTM)

-2.3M

Earnings Growth (Yr)

258.06%

Earnings Growth (Qtr)

382.8%

HCWB Profitability

Operating Margin

98.04%

EBT Margin

-310.10%

Return on Equity

-39.75%

Return on Assets

-8.38%

Free Cashflow Yield

-52.65%

HCWB Investor Care

Shares Dilution (1Y)

502.93%

Diluted EPS (TTM)

-8.01

Revenue & Growth

How HCW Biologics Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025----
20243.9M3.9M3.5M2.6M
20235.8M4.8M3.8M2.8M
2022---6.7M
2021----
2020----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About HCW Biologics Inc.

HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
 CEO
 WEBSITEhcwbiologics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

HCW Biologics Inc. Frequently Asked Questions

HCWB is the stock ticker symbol of HCW Biologics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of HCW Biologics Inc. is 21.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, HCWB's PE ratio (Price to Earnings) is -9.5 and Price to Sales (PS) ratio is 6.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HCWB PE ratio will change depending on the future growth rate expectations of investors.